Kyle Marian Viterbo was regularly tested for the coronavirus, even after being vaccinated. That’s how it was, less than a month after Moderna first jerked off she found she had COVID-19, she traced back to the crowded outdoor antics she attended the week before. Test positive
Vitrerbo, a scientific communicator, understands this is possible because the Moderna vaccine was 94 percent effective in the two weeks after the second injection and about 80 percent after the first injection, although experts caution it is not clear how long it will be prevented. Still, she says it̵7;s “hard to figure out what that percentage of all means in everyday life, especially for the consequences other than my own body. It felt like a sting. ”Fearing an elderly relative where she lived, she checked into a COVID-isolated hotel in New York City, where she rode off a asymptomatic infection and shared her experience. You on TikTok
Last week, the Centers for Disease Control and Prevention reported that more than 5,800 of 75 million people were infected with COVID-19 in the United States. 74 died.The CDC defines the newly developed cases as people who were sick, either asymptomatic or asymptomatic, 14 days or more after completing the vaccine. Some of the headlines on the report implied somewhat irresponsible that advances were made because vaccines were ineffective. For example, CNN puts it this way: “So far, 5,800 people who have been vaccinated have been infected with COVID in the United States. And said the CDC. “
The truth is that successful cases are common and are expected after vaccination. That’s because there are no three vaccines in the United States. For example, the Pfizer / BioNTech vaccine was 95 percent effective. That’s impressively high. But progressive infections, hospitalizations, and deaths still occurred in people who received the vaccine. (What’s a little confusing about the progressive detection of infections is that research uses different terms.There’s a CDC definition of infection two weeks after a full vaccination. But some studies have also examined infection in people who received a single vaccine, such as Viterbo.Other research on post-vaccination infection did not use the term. Breaking through obstacles at all)
“If it’s 95 percent protection, you would expect 5 percent of your files.  Millions of people who are vaccinated will not be protected. Barry Bloom, professor of public health and immunologist at the Harvard TH Chan School of Public Health, said at a press conference Friday. The same logic applies to the Moderna vaccine, which was 94 percent effective, and the Johnson & Johnson vaccine, which was 72 percent effective in the US trial. In fact, the number of successful COVID cases was “less than I expected,” Bloom said, “much less” of the 75 million vaccinated people in the United States. Accounted for only 0.0075 percent.
When you take these percent into account, it’s easier to see that the proportion of successful patients is very low, says Syra Madad, an infectious disease epidemiologist and senior director of the Special Pathogen Program at New York City Health and Hospitals.
The figure is “not about me at all,” she said. Most media coverage was unnecessarily alarming because there was no context, she added.
It is comforting to keep in mind that successful cases often occur with other generic vaccines. For example, annual influenza vaccination is usually only 40 percent to 60 percent effective, meaning those who get vaccinated. Up to 40 percent to 60 percent may still be exposed to the flu if exposed to it, Madad said, the flu could protect about 7.5 million people with influenza in the United States between 2019 and 2020.The more effective COVID-19 vaccine will protect people. Many people
However, Stephen Kissler, an immunology and infectious disease specialist at the Harvard T.H. Chan School of Public Health, warns that the vaccine’s impressive efficacy is not the only reason the proportion of people living with metastatic infections is so small.
For one thing, cases of progressive development can happen only when vaccinated people are exposed to COVID-19, and since most people have been vaccinated recently, they don’t have much time for exposure. Another factor contributing to the decline may be that vaccinated people with an abnormal infection may not be tested because they think they cannot get sick with COVID-19.
For these reasons, the proportion of evolving cases we are seeing now may increase by 0.0075 percent, but Kissler doesn’t think that will change much, “just because vaccines are effective at both preventing disease and reducing the risk of disease.” Spread the infection “
Experts do not yet know why some people are not fully vaccinated.According to Bloom, early unpublished research suggests that some people respond to them by producing the wrong type of antibodies. Rather than making antibodies to the SARS-CoV-2 spike protein, which is supposed to happen, some people seem to produce antibodies against nucleocapsid proteins, and those antibodies have no protective effect either. He said other early research shows that some people do not make antibodies in response to vaccines at all.
The proportion of these people is still “very small – one in a thousand percent – and they have a genetic hang or else they don’t see antigens in the blocking protein,” Bloom said.
The CDC is now collecting data on advanced infections leading to hospitalization and death, looking for patterns related to age, medical conditions, vaccine type, COVID-19 variant, and other factors. This could help experts determine whether COVID-19 deaths or hospitalizations were due to other health-related factors, “even if they may have been vaccinated.” But after 2 weeks they passed and they left. But it may not be directly related to COVID-19, ”Madad said.
It also helps experts figure out how different variables play a role in progressive cases. It’s unclear at this point. “That’s a big question that even many of our doctors and providers have,” she said.
A recent small study of 149 people in Israel, which has not yet been peer reviewed, suggests the B.1.1.7 and B.1.351 strains (first identified in the UK and South Africa, respectively). ) Cause more progressive cases in People who received their first Pfizer / Biotech vaccine A week after the second dosing, variant B.1.351 was making more cases. However, these findings come with two big warnings: no development cases linked to B.1.351 in the two weeks after the second dose, which could mean the vaccine’s reduced efficacy was short-lived. Adi Stern, lead author of the tweet Secondly, although variable B.1.351 does cause some progressive cases. But it is not yet pandemic in Israel, so these cases may not be worth worrying.
All approved vaccines provide protection against known strains that are spread in the United States.That said, it is still important to keep your safety, even if you have received the full vaccine by: This is especially true if it is highly infectious in the community where you live. In the United States). You’ve heard it before, but it’s the same thing: Wear a mask, avoid large gatherings, be it indoors or outdoors.
Viterbo has learned that the hard way in the backyard is full of people who don’t hide from eating and drinking, “continue to get tested for COVID, especially if you come into contact with people who still have it. You haven’t been vaccinated or have never been infected with COVID, ”Viterbo says.“ Get tested when you spend time anonymously in poorly ventilated areas, and yes, that includes eating indoors. ”
Progressive cases will come and may come as a surprise. But rest assured, there is growing evidence showing that the vast majority of fully vaccinated people who are infected have mild symptoms and real-world information about the frequency of patients with HIV / AIDS. Experiencing that problem is quite confident.
“I think overall I am totally amazed that the number of progressive people in America is very low,” said Bloom, “and we should be grateful for that.”
Future Tense is a collaboration of Slate, New America, and Arizona State University that examines emerging technologies, public and social policy.